The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Is perioperative therapy the best strategy for early stage lung cancer?
Jan von der Thüsen, MD, PhD, Erasmus MC, Rotterdam, Netherlands, discusses the benefits of perioperative therapy over adjuvant and neoadjuvant therapy for early stage lung cancer. Rates of recurrence in patients are high after surgery, and the KEYNOTE-671 (NCT03425643) has demonstrated the benefits of perioperative therapy in this setting. However, neoadjuvant therapy has shown to contribute to survival, where immunotherapy can mount a strong immune response. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
